Site icon pharmaceutical daily

Post-traumatic Stress Disorder Treatment Global Market Report 2022: Increasing R&D by Key Players Bolsters Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Post-traumatic Stress Disorder Treatment Market, by Drug Class, by Route of Administration, by Age Group, by Distribution Channel and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.

Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc. Symptoms of PTSD may generate after three months or even after a year. Most of the patients suffering from PTSD show symptoms like intrusive memories, avoidance, negative changes in thinking and changes in emotional and physical reactions.

For instance, sudden death of a loved one may cause PTSD in some people. People with PTSD have heightened sense of danger. According to the U.S. National centre for PTSD, it is estimated that about 15% of the veterans of Vietnam War and 12% of gulf war veterans have PTSD. According to American Psychiatric Association, women are twice likely to get PTSD as compared to men. Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.

Market Dynamics

Increasing research and development activities by the key market players for the treatment of post-traumatic stress disorder is expected to boost the growth of the global post-traumatic stress disorder treatment market over the forecast period. For instance, in December 2021, Jazz Pharmaceuticals plc. a pharmaceutical company, announced that the company had enrolled its first patient in Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme Fatty Acid Amide Hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patient’s associated symptoms such as anxiety, insomnia, and nightmares.

Key Features of the Study:

Detailed Segmentation:

Global Post-traumatic Stress Disorder Treatment Market, By Drug Class

Global Post-traumatic Stress Disorder Treatment Market, By Route of Administration:

Global Post-traumatic Stress Disorder Treatment Market, By Age Group:

Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel:

Global Post-traumatic Stress Disorder Treatment Market, By Region:

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Post-traumatic Stress Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

5. Global Post-traumatic Stress Disorder Treatment Market, By Drug Class, 2017 – 2030, (US$ Million)

6. Global Post-traumatic Stress Disorder Treatment Market, By Route of Administration, 2017 – 2030, (US$ Million)

7. Global Post-traumatic Stress Disorder Treatment Market, By Age Group, 2017 – 2030, (US$ Million)

8. Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)

9. Global Post-traumatic Stress Disorder Treatment Market, By Region, 2017 – 2030, (US$ Million)

10. Competitive Landscape

11. Section

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kcruza

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version